ArticleJournal of proteomics & bioinformatics2012
Article in Journal of proteomics & bioinformatics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Serum antibody screening using glycan arrays.Chemical Society reviews · 2024Review
- Use of a glycomics array to establish the anti-carbohydrate antibody repertoire in type 1 diabetes.Nature communications · 2022Article
- Associations Between Genetically Predicted Plasma N-Glycans and Prostate Cancer Risk: Analysis of Over 140,000 European Descendants.Pharmacogenomics and personalized medicine · 2021Article
- Markers of malignant prostate cancer cells: Golgi localization of α-mannosidase 1A at GM130-GRASP65 site and appearance of high mannose N-glycans on cell surface.Biochemical and biophysical research communications · 2020Article
- Coronaviruses' sugar shields as vaccine candidates.Current trends in immunology · 2020Article
- Glycans as Biomarkers in Prostate Cancer.International journal of molecular sciences · 2019Review
- MALDI Mass Spectrometry Imaging of N-Linked Glycans in Cancer Tissues.Advances in cancer research · 2017Review
- The role of glycans in the development and progression of prostate cancer.Nature reviews. Urology · 2016Review
- Targeting N-glycan cryptic sugar moieties for broad-spectrum virus neutralization: progress in identifying conserved molecular targets in viruses of distinct phylogenetic origins.Molecules (Basel, Switzerland) · 2015Article
- Article
- Uncovering cryptic glycan markers in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE).Drug development research · 2014Article
- Glyco-epitope Diversity: An Evolving Area of Glycomics Research and Biomarker Discovery.Journal of proteomics & bioinformatics · 2014Article
- Anti-Oligomannose Antibodies as Potential Serum Biomarkers of Aggressive Prostate Cancer.Drug development research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Although tumor-associated abnormal glycosylation has been recognized for decades, information regarding host recognition of the evolving tumor glycome remains elusive. We report here a carbohydrate microarray analysis of a number of tumor-associated carbohydrates for their serum antibody reactivities and potential immunogenicity in humans. These are the precursors, cores and internal sequences of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.